Concepedia

Author

Alexandros Xyrafas

Swiss Group For Clinical Cancer Research

Also Known As

A Xyrafas, A. Xyrafas, Alexandros Xyrafas

70

Publications

2K

Citations

20

H-Index

42

Concepts

All Affiliations

Swiss Group For Clinical Cancer ResearchKantonsspital GraubündenUniversity Hospital of HeraklionUniversity Hospital of BaselUniversity Hospital of Lausanne
AX

About

Alexandros Xyrafas is an author at Swiss Group For Clinical Cancer Research specializing in oncology, medicine, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

18

1.2K

2

Health Sciences

5

5

457

3

Public Health

2

2

154

4

Cell Biology

1

1

35

5

Clinical Nutrition

1

1

94

Alexandros Xyrafas

×

28

Publications

1.9K

Citations

19

H-Index

YearCitations

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial

Miklos Pless, Roger Stupp, Hans-Beat Ris,

The Lancet

2015

380

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach,

Clinical Cancer Research

2021

335

Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial

Rolf A. Stahel, Oliver Riesterer, Alexandros Xyrafas,

The Lancet Oncology

2015

196

Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study

Vasilis Georgoulias, V. Bozionelou, Sofia Agelaki,

Annals of Oncology

2012

147

Baseline nutritional evaluation in metastatic lung cancer patients: Mini Nutritional Assessment versus weight loss history

Ioannis Gioulbasanis, Vickie E. Baracos, Zoe Giannousi,

Annals of Oncology

2010

94

Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse

Emmanouil Saloustros, Maria Perraki, Stella Apostolaki,

Breast Cancer Research

2011

83

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)

Andreas Wicki, Nicholas F. Brown, Alexandros Xyrafas,

European Journal of Cancer

2018

62

The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer

Ioannis Gioulbasanis, Athanasios Pallis, Panagiotis J. Vlachostergios,

Lung Cancer

2012

61

Nutritional status, acute phase response and depression in metastatic lung cancer patients: correlations and association prognosis

Zoe Giannousi, Ioannis Gioulbasanis, Athanasios Pallis,

Supportive Care in Cancer

2011

60

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)

Christoph Driessen, Marianne Kraus, Markus Joerger,

Haematologica

2015

57

Page 1